A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma
This is a randomized, double-blind, multi-center, phase III clinical trial designed to evaluate the efficacy of XNW5004 tablets versus Chidamide in Relapsed/Refractory PTCL, with a target of enrolling 120 subjects.
Relapsed/Refractory Peripheral T Cell Lymphoma
DRUG: XNW5004 ; Chidamide placebo|DRUG: XNW5004 placebo; Chidamide
Progression Free Survival (PFS) assessed by BICR, 24 mounths
Objective response rate (ORR), 24 mounths|Time to Response, around 4 months|Duration of response, 24 mounths|Overall survival, around 5 years
This is a randomized, double-blind, multi-center, phase III clinical trial designed to evaluate the efficacy of XNW5004 tablets versus Chidamide in Relapsed/Refractory PTCL, with a target of enrolling 120 subjects.